Results from a survey of people living with HIV in the UK who are aged 15-24 included the optimistic results that younger people might be experiencing less stigma than older HIV-positive people.
Irina Lut from the Family Planning Association presented results from two cross-sectional UK Stigma survey of people living with HIV. This analysis compared results between young people aged 15 to 24 (n=300) and adults >18 years old (n=1450).
Although there are still important difficulties from being HIV positive, the younger group were twice as likely to have a positive self image compared to adults. Young people consistently and significantly reported more positive feelings and less negative feelings compared to adults living with HIV, and reported significantly less stigma. See Table 1.
However the study also reported that younger people are more likely to avoid seeking health care when needed. Also, in conclusion: "while young people experienced less discrimination, a poor experience was more likely to become a barrier to future care".
Table 1: Responses to Stigma Survey From Adults And Young People | ||||
Survey Q | Adults (n=1450) | Young people (n=300) | p | Adj OR (95%CI) A vs.YP |
Treated differently | 441 (30.4%) | 15 (5.0%) | <0.001 | 0.19 (0.099-.037) |
Refused or delayed care | 243 (16.8%) | 9 (3.0%) | <0.001 | 0.45 (0.195-1.03) |
Heard negative comments | 120 (8.3%) | 16 (5.3%) | <0.001 | 0.83 (0.45-1.55) |
Use of excess barrier protection | 202 (13.9%) | 27 (9.0%) | <0.001 | 0.73 (0.45-1.19) |
Avoid seeking care | 396 (27.3%) | 50 (16.7%) | <0.001 | 1.69 (1.13-2.56) |
Reference
Lut I et al, Stigma Survey UK: an intergenerational comparison of stigma and discrimination in non-HIV healthcare settings across the UK. 4th Joint BHIVA/BASHH Conference, 17-20 April 2018, Edinburgh. Poster abstract P127. Published in HIV Medicine, 19 (Suppl. 2), s21-s153.
[Note from TheBodyPRO: This article was originally published by HIV i-Base on May 21, 2018. We have cross-posted it with their permission.]
More Like This
Transition to Adult HIV Care for Youth With Perinatal HIV
Long-Acting ART Update: Viral Rebound Risk; Pediatric Use; Subcutaneous Dosing
![Laura Waters, M.D., FRCP, analyzes new data on injectable cabotegravir/rilpivirine presented at AIDS 2024](https://images.ctfassets.net/rzyyi40064na/16HVSpQ8ivcNNa4OeYXj9d/a769dd2de3d3cff7fcb0ea2e0a4f759d/Laura_Waters_3_3000x2000.jpg?fm=webp&fit=thumb&q=65&w=64&h=64)
This Week in HIV Research: Questions of Engagement
![Two clinicians talk in front of a computer in a lab](https://images.ctfassets.net/rzyyi40064na/6I0lslzvswYMxFNJSsmFEg/a028210b5cac9b4429bd4279122f10eb/01-GettyImages-1291978311.jpg?fm=webp&fit=thumb&q=65&w=64&h=64)
What's New in U.S. HIV Clinical Treatment Guidelines
![nurse patient hands](https://images.ctfassets.net/rzyyi40064na/7qdm9l87peJz0EUtEeEKrh/b80cd8a90aa3f78a6c63d7208a8fbe64/iStock-1058280128.jpg?fm=webp&fit=thumb&q=65&w=64&h=64)